phrykt

Disc Medicine, Inc. (IRON): who owns it and who trades it

As of Nov 16, 2026, IRON insiders reported 97 open-market sales worth $48.8M and no purchases in the last 12 months, with 19% of the sale value made under pre-set 10b5-1 plans. The largest seller was Kevin Bitterman (Director), with $26.7M. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Disc Medicine

From the latest filings

Overall: more selling than buying. Insiders and famous investors mostly sold. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns IRON

216 funds and institutions reported IRON shares worth $3.2B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is FMR LLC (Fidelity) with 12.8%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

FMR LLC (Fidelity)12.8%
BlackRock, Inc.6.5%
Ra Capital Management, L.P.6.4%
JPMorgan Chase & Co4.9%
T. Rowe Price Associates4.9%
Wellington Management Group LLP4.6%
State Street Corp4.3%
Vestal Point Capital, LP4.1%
Atlas Venture Life Science Advisors, LLC4.0%
Vanguard Capital Management LLC3.6%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
FMR LLC (Fidelity)4.89M12.81%$358M-12%
BlackRock, Inc.2.47M6.46%$181M+9%
Ra Capital Management, L.P.2.45M6.41%$179MNo change
JPMorgan Chase & Co1.88M4.91%$140M–
T. Rowe Price Associates1.88M4.91%$137M+21%
Wellington Management Group LLP1.74M4.56%$127M+0%
State Street Corp1.65M4.32%$121M-3%
Vestal Point Capital, LP1.55M4.06%$113M+121%
Atlas Venture Life Science Advisors, LLC1.51M3.96%$111MNo change
Vanguard Capital Management LLC1.37M3.58%$100M-0%
Frazier Life Sciences Management, L.P.1.35M3.55%$99.1MNo change
TCG Crossover Management, LLC1.34M3.51%$98.1MNo change
Bvf Inc1.15M3.02%$84.4M-9%
Woodline Partners LP958,2812.51%$70.1MNo change
Siren, L.L.C.888,4012.33%$65M-10%
Logos Global Management LP875,0002.29%$64M+56%
Opaleye Management Inc.855,0002.24%$62.5M+103%
Geode Capital Management, LLC789,7242.07%$57.8M+6%
Assenagon Asset Management S.A.768,3162.01%$56.2M+41%
Deerfield Management Company, L.P.657,0001.72%$48.1MNo change

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, IRON insiders reported $0 of open-market purchases and $48.8M of sales. 19% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$48.8M
97 trades, 7 people
Sales under a 10b5-1 plan
19%
Share of sale value
Latest trade
Nov 10, 2026
Filed Nov 12, 2026

Purchases and sales by month

$21.8M$21.8MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 10, 2026William Jacob SavageChief Medical OfficerSale plan16,035$85.09$1.4MForm 4
Oct 21, 2026Kevin BittermanDirectorSale plan13,783$80.23$1.1MForm 4
Oct 21, 2026Kevin BittermanDirectorSale plan11,470$80.23$920KForm 4
Oct 21, 2026Kevin BittermanDirectorSale plan266$80.23$21.3KForm 4
Oct 20, 2026Kevin BittermanDirectorSale plan2,869$79.95$229KForm 4
Oct 20, 2026Kevin BittermanDirectorSale plan2,388$79.95$191KForm 4
Oct 20, 2026Kevin BittermanDirectorSale plan55$79.95$4.4KForm 4
Oct 19, 2026Kevin BittermanDirectorSale plan5,937$79.97$475KForm 4
Oct 19, 2026Kevin BittermanDirectorSale plan4,942$79.97$395KForm 4
Oct 19, 2026Kevin BittermanDirectorSale plan115$79.97$9.2KForm 4
Sep 11, 2026Kevin BittermanDirectorSale27,136$70.11$1.9MForm 4
Sep 4, 2026Kevin BittermanDirectorSale plan912$79.96$72.9KForm 4
Sep 4, 2026Kevin BittermanDirectorSale plan18$79.96$1.4KForm 4
Sep 4, 2026Kevin BittermanDirectorSale plan759$79.96$60.7KForm 4
Sep 3, 2026Kevin BittermanDirectorSale plan54$79.98$4.3KForm 4
Sep 3, 2026Kevin BittermanDirectorSale plan2,810$79.98$225KForm 4
Sep 3, 2026Kevin BittermanDirectorSale plan2,339$79.98$187KForm 4
Sep 2, 2026Kevin BittermanDirectorSale plan26,542$80.17$2.1MForm 4
Sep 2, 2026Kevin BittermanDirectorSale plan22,090$80.17$1.8MForm 4
Sep 2, 2026Kevin BittermanDirectorSale plan10$80.98$810Form 4
Sep 2, 2026Kevin BittermanDirectorSale plan9$80.98$729Form 4
Sep 2, 2026Kevin BittermanDirectorSale plan2$80.98$162Form 4
Sep 2, 2026Kevin BittermanDirectorSale plan511$80.17$41KForm 4
Sep 1, 2026Kevin BittermanDirectorSale plan70$79.95$5.6KForm 4
Sep 1, 2026Kevin BittermanDirectorSale plan58$79.95$4.6KForm 4
Sep 1, 2026Kevin BittermanDirectorSale plan1$79.95$80Form 4
Aug 25, 2026Jonathan Yen-Wen YuChief Operating OfficerSale8,796$83.12$731KForm 4
Aug 24, 2026Jonathan Yen-Wen YuChief Operating OfficerSale300$82.53$24.8KForm 4
Aug 17, 2026John D QuiselCEOSale12,712$79.20$1MForm 4
Aug 17, 2026John D QuiselCEOSale11,888$79.84$949KForm 4
Aug 17, 2026John D QuiselCEOSale8,400$78.11$656KForm 4
Aug 12, 2026Jonathan Yen-Wen YuChief Operating OfficerSale804$82.64$66.4KForm 4
Aug 6, 2026Rahul KharaChief Legal OfficerSale5,000$80.00$400KForm 4
Jul 13, 2026John D QuiselCEOSale16,896$74.95$1.3MForm 4
Jul 13, 2026John D QuiselCEOSale6,400$76.05$487KForm 4
Jul 13, 2026John D QuiselCEOSale9,704$74.27$721KForm 4
Jul 7, 2026Jonathan Yen-Wen YuChief Operating OfficerSale100$82.50$8.2KForm 4
Jun 29, 2026Rahul KharaChief Legal OfficerSale1,649$75.00$124KForm 4
Jun 26, 2026Rahul KharaChief Legal OfficerSale851$75.00$63.8KForm 4
Jun 26, 2026Jonathan Yen-Wen YuChief Operating OfficerSale300$72.50$21.8KForm 4
Jun 22, 2026Jonathan Yen-Wen YuChief Operating OfficerSale9,700$72.66$705KForm 4
Jun 18, 2026Rahul KharaChief Legal OfficerSale500$71.62$35.8KForm 4
Jun 18, 2026Rahul KharaChief Legal OfficerSale1,600$70.73$113KForm 4
Jun 18, 2026Rahul KharaChief Legal OfficerSale5,400$69.94$378KForm 4
Jun 18, 2026John D QuiselCEOSale1,551$71.61$111KForm 4
Jun 18, 2026John D QuiselCEOSale9,522$70.70$673KForm 4
Jun 18, 2026John D QuiselCEOSale22,927$69.92$1.6MForm 4
Jun 16, 2026Jonathan Yen-Wen YuChief Operating OfficerSale6,961$69.92$487KForm 4
Jun 16, 2026Jonathan Yen-Wen YuChief Operating OfficerSale11,651$68.76$801KForm 4
Apr 14, 2026Jean M. FranchiCFOSale6,257$69.24$433KForm 4
Apr 13, 2026William Jacob SavageChief Medical OfficerSale2,200$66.81$147KForm 4
Apr 13, 2026William Jacob SavageChief Medical OfficerSale3,531$66.12$233KForm 4
Apr 13, 2026Jean M. FranchiCFOSale400$69.00$27.6KForm 4
Mar 2, 2026William Jacob SavageChief Medical OfficerSale4,392$65.52$288KForm 4
Mar 2, 2026William Jacob SavageChief Medical OfficerSale2,986$66.41$198KForm 4
Feb 25, 2026Jean M. FranchiCFOSale353$69.06$24.4KForm 4
Feb 18, 2026Jean M. FranchiCFOSale3,684$65.89$243KForm 4
Feb 18, 2026Jean M. FranchiCFOSale3,397$65.01$221KForm 4
Feb 17, 2026Jean M. FranchiCFOSale4,075$62.86$256KForm 4
Feb 17, 2026Rahul KharaChief Legal OfficerSale2,853$62.86$179KForm 4
Feb 17, 2026Pamela StephensonChief Commercial OfficerSale5,531$62.86$348KForm 4
Feb 17, 2026William Jacob SavageChief Medical OfficerSale3,256$62.86$205KForm 4
Feb 17, 2026Jonathan Yen-Wen YuChief Operating OfficerSale3,231$62.86$203KForm 4
Feb 17, 2026John D QuiselCEOSale13,264$62.86$834KForm 4
Jan 20, 2026Rahul KharaChief Legal OfficerSale1,000$69.74$69.7KForm 4
Jan 2, 2026Rahul KharaChief Legal OfficerSale1,157$79.27$91.7KForm 4
Jan 2, 2026Rahul KharaChief Legal OfficerSale4,993$78.62$393KForm 4
Jan 2, 2026Rahul KharaChief Legal OfficerSale350$77.67$27.2KForm 4
Dec 17, 2025Kevin BittermanDirectorSale393$91.47$35.9KForm 4
Dec 17, 2025Kevin BittermanDirectorSale148$91.47$13.5KForm 4
Dec 17, 2025Kevin BittermanDirectorSale213$91.47$19.5KForm 4
Dec 16, 2025Kevin BittermanDirectorSale18,666$91.24$1.7MForm 4
Dec 16, 2025Kevin BittermanDirectorSale35,898$91.24$3.3MForm 4
Dec 16, 2025Kevin BittermanDirectorSale14,359$91.24$1.3MForm 4
Dec 15, 2025Kevin BittermanDirectorSale1,572$92.01$145KForm 4
Dec 15, 2025Kevin BittermanDirectorSale11,427$91.18$1MForm 4
Dec 15, 2025Kevin BittermanDirectorSale2,049$92.01$189KForm 4
Dec 15, 2025Kevin BittermanDirectorSale14,811$91.18$1.4MForm 4
Dec 15, 2025Kevin BittermanDirectorSale3,921$92.01$361KForm 4
Dec 15, 2025Kevin BittermanDirectorSale28,913$91.18$2.6MForm 4
Dec 15, 2025Kevin BittermanDirectorSale7,000$91.87$643KForm 4
Dec 15, 2025William Jacob SavageChief Medical OfficerSale300$92.23$27.7KForm 4
Dec 15, 2025William Jacob SavageChief Medical OfficerSale9,151$91.44$837KForm 4
Dec 15, 2025William Jacob SavageChief Medical OfficerSale3,642$90.60$330KForm 4
Dec 12, 2025Kevin BittermanDirectorSale2,005$92.58$186KForm 4
Dec 12, 2025Kevin BittermanDirectorSale16,403$92.05$1.5MForm 4
Dec 12, 2025Kevin BittermanDirectorSale3,852$92.58$357KForm 4
Dec 12, 2025Kevin BittermanDirectorSale3,446$93.80$323KForm 4
Dec 12, 2025Kevin BittermanDirectorSale8,527$92.05$785KForm 4
Dec 12, 2025Kevin BittermanDirectorSale1,793$93.80$168KForm 4
Dec 12, 2025Kevin BittermanDirectorSale6,570$92.05$605KForm 4
Dec 12, 2025Kevin BittermanDirectorSale1,540$92.58$143KForm 4
Dec 12, 2025Kevin BittermanDirectorSale1,371$93.80$129KForm 4
Dec 11, 2025John D QuiselCEOSale2,419$90.97$220KForm 4
Dec 11, 2025John D QuiselCEOSale4,337$92.21$400KForm 4
Dec 11, 2025John D QuiselCEOSale16,356$92.96$1.5MForm 4
Dec 11, 2025John D QuiselCEOSale16,888$93.65$1.6MForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Kevin BittermanDirector–$26.7MOct 21, 2026
John D QuiselChief Executive Officer, Director–$12MAug 17, 2026
William Jacob SavageChief Medical Officer–$3.6MNov 10, 2026
Jonathan Yen-Wen YuChief Operating Officer–$3MAug 25, 2026
Rahul KharaChief Legal Officer–$1.9MAug 6, 2026
Jean M. FranchiChief Financial Officer–$1.2MApr 14, 2026
Pamela StephensonChief Commercial Officer–$348KFeb 17, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

IRON short interest

High short interest. 15.1% of IRON shares are sold short: about 1 share in 7. Over the last 12 reports the number of shares short went up 21%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 6.86M IRON shares were sold short, 15.1% of the shares outstanding, down 8.0% from the report before. At the average daily volume of 2.16M shares, buying them all back would take about 3.2 trading days (days to cover).

Shares short, % of all shares

15.1%May 15Oct 3020.1%

Days to cover

3.2May 15Oct 3028.1

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20266.86M15.07%-8%2.16M3.2
Oct 15, 20267.46M19.42%+3%701,30110.6
Sep 30, 20267.27M18.94%+1%568,31712.8
Sep 15, 20267.21M18.77%-2%528,93213.6
Aug 31, 20267.37M19.18%+0%442,81016.6
Aug 14, 20267.34M19.12%-1%295,88924.8
Jul 31, 20267.39M19.26%+1%353,40120.9
Jul 15, 20267.29M19.09%+15%675,78310.8
Jun 30, 20266.36M16.66%+6%995,1806.4
Jun 15, 20266.01M15.73%+0%427,10814.1
May 29, 20266.00M15.70%+6%411,19714.6
May 15, 20265.67M14.84%+2%537,28910.6

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Disc Medicine company events

Disc Medicine filed 14 reports on Form 8-K in the last 12 months, 1 of them about an important change (job cuts). The latest was on Nov 5, 2026.

  1. Nov 5, 2026ResultsReleased financial results. Filing
  2. Oct 22, 2026AgreementDisc Medicine, Inc. entered into an Underwriting Agreement with Jefferies LLC, Leerink Partners LLC, Morgan Stanley & Co. LLC and Cantor Fitzgerald & Co., as representatives of the several underwriters listed on Schedule I thereto, related to an underwritten public offering by the Company of… Filing
  3. Oct 19, 2026AnnouncementThe Company will host a webcast to discuss topline results from the APOLLO Phase 3 trial of bitopertin in erythropoietic protoporphyria. Filing
  4. Sep 10, 2026AnnouncementThe Company announced initial results from the RESTORE-PV clinical trial of DISC-3405 in patients with PV. The Phase 2, multi-center, open-label RESTORE-PV trial enrolled 40 adult participants with PV, including 20 participants in Cohort A and 20 participants in Cohort B. In the trial, following a… Filing
  5. Jul 30, 2026ResultsReleased financial results. Filing
  6. Jun 30, 2026AgreementDisc Medicine, Inc. entered into a First Amendment to Loan Agreement to the Loan and Security Agreement dated as of November 6, 2024 (as amended, the “Loan Agreement”) among the Company, the lender party thereto and Hercules Capital, Inc., as administrative agent and collateral agent for the… Filing
  7. Jun 24, 2026VoteReported shareholder vote results. Filing
  8. May 5, 2026ResultsReleased financial results. Filing
  9. Feb 27, 2026Job cutsAnnounced job cuts or other exit costs. Filing
  10. Feb 26, 2026ResultsReleased financial results. Filing
  11. Feb 17, 2026AnnouncementShared information with investors. Filing
  12. Feb 13, 2026AnnouncementThe Company received a CRL from the FDA for the Company’s NDA for bitopertin as a treatment for patients with EPP. Item 9.01 Financial Statements and Exhibits. Filing
  13. Jan 12, 2026ResultsReleased financial results. Filing
  14. Dec 8, 2025AnnouncementDisc Medicine, Inc. held a previously-announced conference call and webcast to review the Company's data presented at the 67th American Society of Hematology Annual Meeting and Exposition and the Company's operational plans. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Disc Medicine financials

Famous investors that hold IRON

3 of the 50 well-known investors we track reported holding IRON in their latest 13F filing. The largest position is Ken Griffin's, worth $8.6M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 2026131,347$8.6M0.0%-37%
Israel Englander · Millennium ManagementQ3 202653,214$3.5M0.0%-50%
Paul Tudor Jones · Tudor Investment CorpQ3 202627,846$1.8M0.0%-3%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named IRON in the last 120 days.

FiledHolderFormStake
Oct 26, 2026AI DMI LLC13D/A6.6%
Oct 26, 2026AI DMI LLC13D/A6.6%

Questions about Disc Medicine, Inc. (IRON) stock

Who owns the most IRON stock?

The largest reported owner of Disc Medicine, Inc. (IRON) is FMR LLC (Fidelity), with 12.8% of the company. In total, 216 funds and institutions reported holding IRON at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are IRON insiders buying or selling?

In the last 12 months, IRON insiders reported no open-market purchases and 97 sales worth $48.8M. The latest trade was on Nov 10, 2026. See every trade.

What is the short interest in IRON?

As of Oct 30, 2026, 6.86M IRON shares were sold short, 15.1% of the shares outstanding, down 8.0% from the report before. At the average daily volume of 2.16M shares, buying them all back would take about 3.2 trading days (days to cover). See the history.

Which famous investors hold IRON?

3 of the 50 well-known investors we track reported IRON in their latest 13F filing, including Ken Griffin, Israel Englander, Paul Tudor Jones. The largest position is worth $8.6M. See all holders.

Executive pay

Disc Medicine's chief executive was paid a total of $10M for the year ended Dec 31, 2025, up 10% from $9.1M the year before. In the last 12 months, Disc Medicine's executives and directors bought no stock on the open market and sold $48.8M.

Chief executive, total pay$10MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$13.5MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$3.8MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.